Table 3.

Adverse events

	T + P (n = 68)		T + C (n = 70)
	n	(%)	n	(%)
AEs	32	(47.1)	42	(60.0)
Drug‐related AEs	8	(11.8)	7	(10.0)
Serious AEs	2	(2.9)	1	(1.4)
Serious drug‐related AEs	1	(1.5)	0	(0)
AEs leading to discontinuation	2	(2.9)	2	(2.9)
Drug‐related AEs leading to discontinuation	1	(1.5)	1	(1.4)
AEs of special interest
Hypoglycaemia	0	(0)	0	(0)
Urinary tract infection	1	(1.5)	0	(0)
Fracture	0	(0)	1	(1.4)
Blood ketone bodies increased	2	(2.9)	2	(2.9)
Cardiovascular‐related events	2	(2.9)	1	(1.4)
Skin and subcutaneous tissue disorders	2	(2.9)	7	(10.0)
Gastrointestinal disorders	1	(1.5)	10	(14.3)
Hepatic function impairment	2	(2.9)	0	(0)

Abbreviations: AE, adverse event; T + C, teneligliptin plus canagliflozin; T + P, teneligliptin plus placebo.